Remove Business Development Remove Development Remove Life Science
article thumbnail

TANAKA Contributes to Ambix Life Science Fund

Pharma Mirror

and operates the TANAKA Precious Metals manufacturing business, announced today that TANAKA made an equity contribution to Ambix Life Science Fund I, L.P., The post TANAKA Contributes to Ambix Life Science Fund appeared first on Pharma Mirror Magazine. Background to and Objectives.

article thumbnail

6 research and development life sciences predictions for 2023

pharmaphorum

From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences teams to collaborate efficiently and effectively in 2023. Simplicity and technology intersect to streamline drug development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novel Approaches in Cancer Immunotherapy — Featuring OncoC4 founder, CEO and CSO Dr. Yang Liu and CFO Abid Ansari – Xtalks Life Science Podcast Ep. 146

XTalks

This episode features an interview with Yang Liu, PhD, founder, chairman, CEO and chief scientific officer; and Abid Ansari, MBA, Chief Financial Officer at OncoC4 , a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

article thumbnail

Revolutionizing Orthopedic Joint Replacement — Interview with Ben Sexson, Co-Founder, CEO, Monogram Orthopedics – Xtalks Life Science Podcast Ep. 142

XTalks

Monogram is focused on developing patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. Ben is an engineer by training and before joining Monogram, he served as the Director of Business Development at Pro-Dex, an OEM manufacturer of Orthopedic Robotic End-Effectors.

article thumbnail

Singapore startup Albatroz wins financing to develop solid tumour drugs

Pharmaceutical Technology

This investment will be used to further the development of the Singapore-based pharmaceutical company’s solid tumour-focused monoclonal antibodies. The funding and a prize-win from Amgen will support the company’s drug development plans as Singapore continues developing its pharmaceutical market.

article thumbnail

IWD: Spotlight on women in life sciences

pharmaphorum

How did you get into life sciences? After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. What has your career path been?

article thumbnail

Neumora raises funds for precision neuro therapies development

Pharmaceutical Technology

New and existing investors including F-Prime Capital, Altitude Life Science Ventures, Mubadala Capital, Amgen, Exor Ventures, ARCH Venture Partners, Invus, Abu Dhabi Growth Fund (ADG), Newpath Partners, Polaris Partners, as well as other undisclosed investors have participated in the financing round.